Clinical Trials Logo

Clinical Trial Summary

Glaucoma is one of the leading causes of blindness worldwide. The key feature of glaucoma is damage to the optic nerve head with loss of retinal ganglion cells and local tissue remodeling. Neuronal cell death in glaucoma occurs by apoptotic mechanisms1. Apoptosis of neurons also plays a major role in neurodegenerative diseases, such as Alzheimer's or Parkinson's disease. An association between glaucoma and these disorders has been described 2-4. Furthermore, it has been reported that the olfactory function is disturbed in these neurodegenerative diseases5-6. We hypothesize that similar olfactory alterations may occur in glaucoma which is in fact a local neurodegenerative disease.


Clinical Trial Description

1. Introduction

1. Background and rationale of the study Glaucoma is one of the leading causes of blindness worldwide. The key feature of glaucoma is damage to the optic nerve head with loss of retinal ganglion cells and local tissue remodeling. Neuronal cell death in glaucoma occurs by apoptotic mechanisms1. Apoptosis of neurons also plays a major role in neurodegenerative diseases, such as Alzheimer's or Parkinson's disease. An association between glaucoma and these disorders has been described 2-4. Furthermore, it has been reported that the olfactory function is disturbed in these neurodegenerative diseases5-6. We hypothesize that similar olfactory alterations may occur in glaucoma which is in fact a local neurodegenerative disease.

2. Study objectives Primary Objective: To test the olfactory function in glaucoma patients.

3. Investigational plan Chronic glaucoma patients will be assessed regarding inclusion/exclusion criteria and clinical criteria. A basic otorhinolaryngological examination addressing the possible exclusion criteria will be performed prior to the Sniffing Sticks test battery. A simple questionnaire regarding an olfactory status of the patient will be filled out. The olfactory performance of glaucoma patients will be compared to the existing age-matched normative database.

4. Design Single center cohort study, normative database as control.

5. Selection of study population

I. Number of subjects Thirty consecutive glaucoma patients, age 18 - 70, will be recruited from the glaucoma consultation at the University Eye Clinic Basel.

II. Prestudy screening A detailed medical and ophthalmic history will be recorded and all patients will complete an ophthalmologic examination (best corrected visual acuity, intraocular pressure measurements, slit-lamp examination, indirect fundoscopy) as well as an otorhinolaryngological examination.

III. Inclusion criteria Diagnosis of chronic open-angle glaucoma will be based on the presence of typical glaucomatous disc damage and visual field defects. Only patients with a recent gonioscopic examination and at least two visual field examinations will be recruited.

IV. Exclusion criteria Occludable iridocorneal angles, a history of current, chronic or recurrent inflammatory eye disease, a history of retinal or neuroophthalmologic disease that could result in visual field defects, need for any concomitant medications that may interfere with the evaluation of olfactory function, a history of past or active alcohol or drug abuse, smoking, a history of olfactory disturbance related to identifiable local factors, and any local condition that could lead to hyposmia/anosmia or interfere with the olfactory function, such as polyps, chronic sinus infection, sub(acute) viral or bacterial infection, history of sinus surgery, will be considered as an exclusion criterion.

V. Study medication NA

6. Study protocol I. General restrictions on subjects NA

II. Dietary restriction NA.

III. Description of study days On the experimental day a detailed history will be taken and a complete ophthalmologic examination including best corrected visual acuity, slit-lamp examination, indirect fundoscopy, and intraocular pressure measurement will be performed (KG). Based on these examinations and chart data, the patient shall be classified as glaucoma patient. A basic otorhinolaryngological screening examination will follow, the patient will fill an olfactory questionnaire and the Sniffing Sticks test battery will be performed (AWL).

7. Efficacy variables I. Outcome variables Odor threshold score (0-16), odor discrimination task score (0-16), Odor identification score (0-16), composite score (sum of the three above).

II. Follow-up safety investigations NA

2. Methods of evaluation

a. Sniffing Sticks test battery7 Commercially available felt-tip pens, 14 cm long and with an inner diameter of 1.3 cm, are filled with 4 mL of liquid odorants or odorants dissolved in propylene glycol. For odor presentation the cap is removed by the experimenter for approximately 3 seconds and the pen`s tip is placed 2 cm in front of the examined nostril. Three tests are performed. Odor threshold for n-butanol is assessed using a single-staircase, triple-forced choice procedure. Sixteen dilutions are prepared. Three pens are presented at randomized order, with two containing only the solvent. The patient's task is to identify the odor-containing pen. The score ranges from 0 to 16. In the odor-discrimination test, the patient has to determine which of the three presented pens smell differently. A total of 16 triplets is presented to the patient, and thus the score ranges from 0 to 16. Odor identification is assessed by means of 16 common odors, using a multiple choice technique with a list of four descriptors. The score ranges also from 0 to 16. The composite score is the sum of three scores.

3. Statistical procedures

1. Biometric methods Mann-Whitney U-test, p<0.05 being considered significant.

2. Statistical model Olfactory scores of glaucoma patients will be compared to the age-matched normative database by means of Mann-Whitney U-test.

3. Study power No power calculations were performed, as there are no prior pilot studies. ;


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00304824
Study type Observational
Source University Hospital, Basel, Switzerland
Contact
Status Completed
Phase N/A
Start date October 2004
Completion date November 2005

See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A